Printer Friendly

CEL-SCI ENTERS PROCESS DEVELOPMENT AGREEMENT WITH ROGER WILLIAMS MEDICAL CENTER

 CEL-SCI ENTERS PROCESS DEVELOPMENT AGREEMENT
 WITH ROGER WILLIAMS MEDICAL CENTER
 ALEXANDRIA, Va., Sept. 16 /PRNewswire/ -- CEL-SCI Corporation (NASDAQ: CELI) announced today the signing of a Process Development Agreement with Roger Williams Medical Center in Providence, R.I. The new agreement is designed to improve CEL-SCI Corporation's production methods for the manufacture of its immune boosting product, BC-IL. The scientific director of the program is Dr. Nicola Kouttab, director of clinical immunology at Roger Williams Medical Center.
 CEL-SCI Corporation has pioneered the development of combination therapy using "natural" lymphokine and cytokine mixtures ("cocktails") for the treatment of cancers and immunodeficiencies. Its 50 percent owned subsidiary, Viral Technologies, Inc., is developing the HGP-30 AIDS vaccine/treatment based on a piece of the p17 core protein.
 -0- 9/16/92
 /CONTACT: Matt Haines of Strategic Growth International, 212-826-9622, or Daryll Strahl, 303-979-5735, both for CEL-SCI/
 (CELI) CO: CEL-SCI Corporation; Roger Williams Medical Center ST: Virginia IN: MTC SU:


DC -- DC002 -- 9965 09/16/92 09:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 16, 1992
Words:164
Previous Article:PRECISION AEROTECH REPORTS FIRST QUARTER RESULTS
Next Article:THE NEW STOUFFER CONCOURSE HOTEL ANNOUNCES OVER 375 JOB OPENINGS
Topics:


Related Articles
CEL-SCI CORPORATION ANNOUNCES ESTABLISHMENT OF PRODUCTION FACILITY
CEL-SCI CORPORATION ANNOUNCES THE ADDITION OF A NEW MEMBER TO ITS SCIENTIFIC ADVISORY BOARD
CEL-SCI CORPORATION TO LICENSE POTENTIAL DRUG TREATMENT FOR MULTIPLE SCLEROSIS
CEL-SCI Makes Final Payment for Vaccine Technology
CEL-SCI Corporation Extends Agreement with U.S. Navy For Malaria Vaccine Collaboration
CEL-SCI Corporation and University of Nebraska Announce Research Grant With HGP-30 AIDS Vaccine.
CEL-SCI Starts Cancer Collaboration in Germany.
CEL-SCI Corporation Starts Another Collaboration With the National Cancer Institute.
CEL-SCI Enters Agreement With University of Arkansas Medical Center For Evaluation of CEL-1000 Against Genital Chlamydia.
CEL-SCI Enters Agreement With Proxima Concepts For Development of Oral Forms of CEL-1000 Compound.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters